Jump To Section
Featured Stories

AstraZeneca Buys Into COVID-19 Antibodies From Newly Launched RQ Bio
The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.

Stock Watch: One Acquisition Does Not Make A Biotech M&A Boom
Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.

Gilead’s Lenacapavir On The Move Again As FDA Lifts Clinical Hold
The long-acting HIV drug’s greatest potential is for pre-exposure prophylaxis, where it would compete against ViiV’s long-acting injectable Apretude.
Asia Spotlight
How Ex-Janssen India Chief Is Steering Bharat Serums’ Ambitions In Women’s Health
Sanjiv Navangul, managing director and CEO, Bharat Serums and Vaccines, in a wide-ranging interview with Scrip, outlines the firm’s game plan to establish itself as a “force to reckon with” in women’s health - it goes beyond drugs and encompasses devices and potentially digital therapeutics as well. The former Janssen India chief also weighs in on the worrying industry-wide input cost escalation scenario and supply chain turbulence.
Latest News
Scrip Podcast
Insights and perspectives on commercial, R&D,
deal-making and business strategy developments.
More Podcasts
Infographics

Who Were Big Pharma's Top Deal-Makers In 2021?
INFOGRAPHIC: Roche/Genentech was the busiest deal-maker in big pharma for second consecutive year in 2021, followed by Sanofi, Takeda, Lilly, Novartis and Pfizer.

Bugs As Drugs: The Budding Microbiome Modulator Pipeline
INFOGRAPHIC: The sheer number of micro-organisms in the human body and their functions makes the microbiome a ripe target for therapeutic intervention. While still rather early, data show the microbiome modulator pipeline has immense potential across a range of therapeutic areas, not just in gastrointestinal disease.

Scorching COVID-19 Era Returns From India Biotech, Healthcare Funds Outpace The Globe
Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.
Commercial Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Commercial
Asia Deal Watch: Taiho Brings Cullinan Pearl Back In House
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.
Valneva Hits New COVID-19 Jab Low With EC Contract Termination
Less than a year after signing a major advance purchase agreement to supply its inactivated COVID-19 jab to the EU, Valneva is faced with a termination that could hit its 2022 guidance.
Boryung’s Two-Track R&D Strategy: Innovative Drugs And Cash Cows
Boryung’s chief technology officer outlines R&D strategy to move forward as a Korea-based global pharma firm and how domestic pharmas are juggling new drug development and generating cash cows.
Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal
Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.
Kriya Raises $270m To Scale Gene Therapy Platform, Move Into The Clinic
The start-up is built around four business units – technology, manufacturing, R&D and therapeutics – based on internal and external expertise. Kriya will take its first gene therapies into the clinic in 2023.
Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.
Policy & Regulation Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Policy & Regulation
UCB Rocked By US FDA Rejection Of Blockbuster-In-Waiting Bimzelx
The Belgian group’s US launch of Bimzelx could be delayed by up to a year after the FDA hit UCB with a complete response letter which states that "certain pre-approval inspection observations must be resolved” before the drug can get the green light for psoriasis.
Lecanemab Filing Complicates Biogen's Hunt For New CEO
Lecanemab is now filed for accelerated approval with the US FDA, but the wait for a Phase III readout could impact the hunt for Biogen’s next CEO.
Eisai’s Lecanemab BLA Filing A Key Step For Ailing Biogen
Aduhelm commercialization was a bust, so Biogen’s next big hope for a potential blockbuster Alzheimer’s therapy is partner Eisai’s amyloid protofibril-targeting antibody lecanemab.
Research & Development
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Research & Development
Valneva Hits New COVID-19 Jab Low With EC Contract Termination
Less than a year after signing a major advance purchase agreement to supply its inactivated COVID-19 jab to the EU, Valneva is faced with a termination that could hit its 2022 guidance.
Boryung’s Two-Track R&D Strategy: Innovative Drugs And Cash Cows
Boryung’s chief technology officer outlines R&D strategy to move forward as a Korea-based global pharma firm and how domestic pharmas are juggling new drug development and generating cash cows.
Bristol’s Opdivo Stumbles On Its Way To First-Line Bladder Cancer Indication
The CheckMate-901 trial failed on one of its primary endpoints, but the company will continue the trial to explore additional primary endpoints.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.